Arbutus Biopharma (ABUS) Amortization of Goodwill (2019)

Arbutus Biopharma's (ABUS) quarterly Amortization of Goodwill came in at $22.5 million in Q3 2019.

Arbutus Biopharma (ABUS) Amortization of Goodwill (2019) Analysis & Trends

Arbutus Biopharma has disclosed Amortization of Goodwill across 1 years of filings, most recently posting $22.5 million for Q3 2019.

Amortization of Goodwill for Q3 2019 came in at $22.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $22.5 million (changed 0.0% YoY), and the FY2019 annual result was $22.5 million, changed N/A from the prior year.
Amortization of Goodwill came in at $22.5 million for Q3 2019 at Arbutus Biopharma.
In the past five years, Amortization of Goodwill ranged from a high of $22.5 million in Q3 2019 to a low of $22.5 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Arbutus Biopharma	882.62 Mn	882.62 Mn	-

Download Data

Date	Value
Sep 30, 2019	22.47 Mn
Sep 30, 2019	22.47 Mn